Sirona Medical Raises $40M Series D as Platform Usage Triples
Round led by Avidity Partners. Platform usage, ARR, & contracted ARR all grew by more than 2.5x year-over-year.…
New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…
Oracle and Buck Institute for Research on Aging Advance Landmark Federal Aging Research Initiative
Buck Institute aims to advance bioinformatics using Oracle Life Sciences Data Intelligence to transform aging research into a…
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02…
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
Mississauga, ON, July 15, 2026 /PRNewswire/ – Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare…
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
MISSISSAUGA, ON, May 26, 2026 /CNW/ – Novo Nordisk Canada is announcing that effective Friday, May 29, 2026,…
Vi Launches Suite of AI Agents for Healthcare, Life Sciences, and Wellness Enterprises; Completes $145M Transaction at $1.64B Valuation
NEW YORK, May 19, 2026 /PRNewswire/ — Vi, the enterprise-AI platform for health, today announced a new suite…
Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
TORONTO, May 14, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), the largest Canadian‑based global health company,…
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Ajax’s lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with…
Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company…
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme’s Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Partnership unites Illumina’s leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for…